20 YEARS OF DRUG DEVELOPMENT EXPERTISE
7 HIGH-PROFILE DRUG APPROVALS
1 GOAL—GETTING YOUR DRUG TO MARKET QUICKLY AND SUCCESSFULLY

CORE VALUES

PASSION • INTEGRITY • FOCUS

OUR FOUNDERS

MARK MENNING, PhD

A little more than a decade ago, a single-tablet regimen for HIV was a dream. But working with a team at Gilead, Mark pioneered the first single tablet, once daily, combination therapy, Atripla® (2006), helping to radically transform the treatment of the disease. He went on to create Complera®, the second single-tablet regimen, firmly establishing himself as a both a pioneer and an expert in combination therapies, making it easier for patients to get the treatments they need.

In addition to his decade of development experience at Gilead, Mark has also held scientific and management roles at Actera Pharmaceuticals, Tobira Therapeutics, Amgen, and DuPont Pharmaceuticals. Besides Atripla® and Complera®, Mark led the formulation/process development and participated in NDA authoring of multiple fixed-dose combination products for the treatment of HIV/AIDS and is a co-inventor of Truvada®, Stribild®, Vitekta™, and Tybost™ tablets.

Mark received a BSChE from the Ohio State University and has a PhD in Chemical and Bioprocess Engineering from University College Dublin.

LARA PARK MENNING, MSc, PMP

When a multinational company has scientists around the world racing to get a drug to market, the demands it places on a project manager are intense, and lack of effective management can stop a project dead in its tracks. Working with pharma giants like Genentech, Patheon and Laboratories Pierre Fabre (France), Lara honed her management mastery, shepherding complex projects successfully through the often-byzantine path from lab to launch.

Lara is a Project Management Professional (PMP) and achieved a dual MSc. in Biotechnology and Biochemistry from L’Universtié de Paul Sabatier and in International Management from IAE Business School (l’Institut d’Administration d’Entreprises) in France.

LET’S WORK TOGETHER